Plasmacytoma

12 registered clinical trials studyying Plasmacytoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma NCT06429150	Shenzhen Geno-Immune Medical Institute	Phase 1 / Phase 2
Active Not Recruiting	A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma NCT04174196	Memorial Sloan Kettering Cancer Center	Phase 2
Unknown	Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma NCT04065308	Seoul National University Hospital	Phase 2
Terminated	Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma NCT03031730	National Cancer Institute (NCI)	Phase 1
Terminated	Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma NCT03312868	Instituto do Cancer do Estado de São Paulo	Phase 2
Active Not Recruiting	Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma NCT02544308	University College, London	Phase 3
Completed	Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome NCT02921893	Mayo Clinic	EARLY_Phase 1
Completed	Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myelom NCT02547662	Mayo Clinic	Phase 2
Completed	Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patie NCT02506959	M.D. Anderson Cancer Center	Phase 2
Completed	Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer NCT02184533	Stanford University	Phase 1
Completed	Phase I/II Study of hLL1 in Multiple Myeloma NCT00421525	Gilead Sciences	Phase 1 / Phase 2
Terminated	S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma NCT00109889	SWOG Cancer Research Network	Phase 2